LU90160I2 - Naratriptan facultativement sous la forme d'un sel pharmaceutiquement acceptable ou d'un solvate y compris le chlorhydrate de naratriptan - Google Patents

Naratriptan facultativement sous la forme d'un sel pharmaceutiquement acceptable ou d'un solvate y compris le chlorhydrate de naratriptan

Info

Publication number: LU90160I2
Authority: LU; Luxembourg
Prior art keywords: naratriptan; pharmaceutically acceptable; optionally; acceptable salt; hydrochloride
Prior art date: 1987-08-13

Application number

LU90160C

Other languages

English (en)

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-08-13

Filing date

1997-10-31

Publication date

1998-01-14

1987-08-13 Priority claimed from GB878719167A external-priority patent/GB8719167D0/en

1988-06-14 Priority claimed from GB888814002A external-priority patent/GB8814002D0/en

1988-06-17 Priority claimed from GB888814481A external-priority patent/GB8814481D0/en

1997-10-31 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

1998-01-14 Publication of LU90160I2 publication Critical patent/LU90160I2/fr

Links

150000003839 salts Chemical class 0.000 title abstract 2
239000012453 solvate Substances 0.000 title abstract 2
AWEZYKMQFAUBTD-UHFFFAOYSA-N Naratriptan hydrochloride Chemical compound [H+].[Cl-].C12=CC(CCS(=O)(=O)NC)=CC=C2NC=C1C1CCN(C)CC1 AWEZYKMQFAUBTD-UHFFFAOYSA-N 0.000 title 2
229960005254 naratriptan Drugs 0.000 title 1
229960004021 naratriptan hydrochloride Drugs 0.000 title 1
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
206010009094 Chronic paroxysmal hemicrania Diseases 0.000 abstract 1
208000006561 Cluster Headache Diseases 0.000 abstract 1
206010019233 Headaches Diseases 0.000 abstract 1
208000019695 Migraine disease Diseases 0.000 abstract 1
208000018912 cluster headache syndrome Diseases 0.000 abstract 1
231100000869 headache Toxicity 0.000 abstract 1
150000004677 hydrates Chemical class 0.000 abstract 1
239000000543 intermediate Substances 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
206010027599 migraine Diseases 0.000 abstract 1
208000007777 paroxysmal Hemicrania Diseases 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
208000019553 vascular disease Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Indole Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Peptides Or Proteins (AREA)

LU90160C 1987-08-13 1997-10-31 Naratriptan facultativement sous la forme d'un sel pharmaceutiquement acceptable ou d'un solvate y compris le chlorhydrate de naratriptan LU90160I2 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB878719167A GB8719167D0 (en)	1987-08-13	1987-08-13	Chemical compounds
GB888814002A GB8814002D0 (en)	1988-06-14	1988-06-14	Chemical compounds
GB888814481A GB8814481D0 (en)	1988-06-17	1988-06-17	Chemical compounds

Publications (1)

Publication Number	Publication Date
LU90160I2 true LU90160I2 (fr)	1998-01-14

Family

ID=27263551

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU90160C LU90160I2 (fr)	1987-08-13	1997-10-31	Naratriptan facultativement sous la forme d'un sel pharmaceutiquement acceptable ou d'un solvate y compris le chlorhydrate de naratriptan

Country Status (28)

Country	Link
US (1)	US4997841A (fr)
EP (1)	EP0303507B1 (fr)
JP (1)	JPH0633252B2 (fr)
KR (1)	KR0131327B1 (fr)
AT (1)	ATE92057T1 (fr)
AU (1)	AU611469B2 (fr)
CA (1)	CA1310968C (fr)
CY (1)	CY1728A (fr)
CZ (1)	CZ404291A3 (fr)
DE (2)	DE3882614T2 (fr)
DK (1)	DK172696B1 (fr)
ES (1)	ES2058292T3 (fr)
FI (1)	FI92397C (fr)
GB (1)	GB2208646B (fr)
HK (1)	HK86793A (fr)
HU (1)	HU211576A9 (fr)
IE (1)	IE61488B1 (fr)
IL (1)	IL87437A0 (fr)
LU (1)	LU90160I2 (fr)
LV (1)	LV5736B4 (fr)
NL (1)	NL970035I2 (fr)
NO (2)	NO174052C (fr)
NZ (1)	NZ225820A (fr)
PH (1)	PH24976A (fr)
PT (1)	PT88255B (fr)
SG (1)	SG65393G (fr)
SK (1)	SK281495B6 (fr)
UY (1)	UY23657A1 (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8819024D0 (en) *	1988-08-10	1988-09-14	Glaxo Group Ltd	Chemical compounds
GB8903036D0 (en) *	1989-02-10	1989-03-30	Glaxo Group Ltd	Chemical compounds
PT97888B (pt) *	1990-06-07	1998-12-31	Zeneca Ltd	Processo para a preparacao de compostos heterociclicos derivados de indol e de composicoes farmaceuticas que os contem
DK152090D0 (da) *	1990-06-22	1990-06-22	Lundbaek A S H	Piperidylsubstituerede indolderivater
US5643784A (en) *	1990-12-04	1997-07-01	H, Lundbeck A/S	Indan derivatives
NZ243065A (en)	1991-06-13	1995-07-26	Lundbeck & Co As H	Piperidine derivatives and pharmaceutical compositions
TW222631B (fr) *	1991-07-15	1994-04-21	Duphar Int Res
GB9209882D0 (en) *	1992-05-07	1992-06-24	Glaxo Lab Sa	Compositions
GB9211277D0 (en)	1992-05-28	1992-07-15	Glaxo Group Inc	Pharmaceutical compositions
FI950486A0 (fi) *	1992-08-05	1995-02-03	Wyeth John & Brother Ltd	Amidijohdannaiset
GB9320115D0 (en) *	1993-09-29	1993-11-17	Glaxo Group Ltd	Process
US5521196A (en) *	1994-10-05	1996-05-28	Eli Lilly And Company	5-HT1F agonists for the treatment of migraine
US5521197A (en) *	1994-12-01	1996-05-28	Eli Lilly And Company	3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists
FR2731224B1 (fr) *	1995-03-02	1997-05-30	Pf Medicament	Nouveaux derives bi-tryptaminiques sulfonamides, leur procede de preparation et leur utilisation a titre de medicaments
FR2731222A1 (fr) *	1995-03-02	1996-09-06	Pf Medicament	Nouveaux derives de piperazine aminoindoles cycliques, leur procede de preparation et leur utilisation a titre de medicaments
WO1996029075A1 (fr) *	1995-03-20	1996-09-26	Eli Lilly And Company	5-substitue-3-(1,2,3,6-tetrahydropyridine-4-yl)- et 3-(piperidine-4-yl)-1h-indoles: nouveaux antagonistes 5-ht¿1f?
WO1997033579A1 (fr) *	1996-03-13	1997-09-18	Glaxo Group Limited	Medicaments comprenant des agonistes du recepteur de type 5ht1 presentant une meilleure absorption
AR013669A1 (es) *	1997-10-07	2001-01-10	Smithkline Beecham Corp	Compuestos y metodos
US6066092A (en) *	1997-11-06	2000-05-23	Cady; Roger K.	Preemptive prophylaxis of migraine device and method
US7189753B1 (en)	1997-11-06	2007-03-13	Cady Roger K	Preemptive prophylaxis of migraine
IL153605A0 (en)	2000-07-21	2003-07-06	Lundbeck & Co As H	Indole derivatives useful for the treatment of cns disorders
ATE374192T1 (de) *	2000-11-29	2007-10-15	Lilly Co Eli	1-(2-m-methansulfonamidophenylethyl)-4-(m- trifluoromethylphenyl)piperazine und ihre akzeptablen pharmazeutischen salze und solvate und ihre verwendung zur behandlung von inkontinenz
US8329734B2 (en)	2009-07-27	2012-12-11	Afgin Pharma Llc	Topical therapy for migraine
EP2316468A1 (fr)	2002-02-22	2011-05-04	Shire LLC	Système de distribution et méthodes de protection et d'administration de dextroamphetamine
US20070065463A1 (en)	2003-06-20	2007-03-22	Ronald Aung-Din	Topical therapy for the treatment of migranes, muscle sprains, muscle spasms, spasticity and related conditions
MX2007005845A (es) *	2004-11-24	2007-07-04	Alcon Inc	Metodo para entregar rocio nasal.
CA2666149A1 (fr) *	2006-10-19	2008-04-24	Auspex Pharmaceuticals, Inc.	Indoles substitues
WO2008056378A2 (fr) *	2006-11-09	2008-05-15	Natco Pharma Limited	Nouveau procédé destiné à la préparation de naratriptan
WO2008072257A2 (fr) *	2006-12-12	2008-06-19	Ind-Swift Laboratories Limited	Procédé de préparation de dérivés de l'indole
WO2009016466A2 (fr) *	2007-07-30	2009-02-05	Orchid Chemicals & Pharmaceuticals Limited	Procédé de préparation de chlorhydrate de naratriptan
WO2009118753A2 (fr) *	2008-03-07	2009-10-01	Usv Limited	Procédé de préparation de chlorhydrate de naratriptane
JP2011526889A (ja)	2008-06-30	2011-10-20	アフギンファーマ，エルエルシー	局所局部的神経作用療法
WO2010004580A2 (fr) *	2008-07-11	2010-01-14	Ind-Swift Laboratories Limited	Procédé de préparation de dérivés d'indole
WO2010084507A2 (fr) *	2008-07-15	2010-07-29	Sun Pharmaceutical Industries Ltd.	Procédé de synthèse du n-méthyl-2-[3-(1-méthyl-4-pipéridyl)-1h-indol-5-yl]-éthanesulfonamide et de ses sels d'addition acide
NZ597620A (en)	2009-08-20	2013-08-30	Cipla Ltd	A process for the synthesis of naratriptan
CN102276581B (zh) *	2011-08-05	2013-06-12	上海师范大学	N-取代四氢吡啶连吲哚类化合物及其制备方法及应用
HK1244715A1 (zh)	2015-03-02	2018-08-17	阿福金制药有限责任公司	用大麻素的局部区域神经影响性疗法
US10383816B2 (en)	2015-03-02	2019-08-20	Afgin Pharma, Llc	Topical regional neuro-affective therapy with cannabinoid combination products
US20180049994A1 (en)	2016-08-16	2018-02-22	Afgin Pharma, Llc	Topical regional neuro-affective therapy with caryophyllene
EP3766483A1 (fr)	2019-07-19	2021-01-20	BioPharma Synergies, S. L.	Composition de poudre orodispersible comprenant un triptane

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2362628A1 (fr) *	1976-08-26	1978-03-24	Roussel Uclaf	Nouveaux derives du piperidyl-indole et leurs sels, procede de preparation et application a titre de medicaments
FR2421899A1 (fr) *	1978-01-16	1979-11-02	Roussel Uclaf	Nouveaux derives du tetrahydropyridinyl-indole et leurs sels, le procede de preparation et l'application a titre de medicaments de ces nouveaux produits
IT1170387B (it) *	1982-06-07	1987-06-03	Glaxo Group Ltd	Composti eterociclici, procedimento per prepararli e composizioni farmaceutiche che li contengono
FR2533924A1 (fr) *	1982-10-05	1984-04-06	Roussel Uclaf	Nouveaux derives du 4-(1h-indol-3-yl)a-methyl piperidine-1-ethanol, leurs sels, le procede de preparation, l'application a titre de medicaments et les compositions les renfermant
GB8332435D0 (en) *	1983-12-06	1984-01-11	Glaxo Group Ltd	Chemical compounds
GB8332437D0 (en) *	1983-12-06	1984-01-11	Glaxo Group Ltd	Chemical compounds
DE3419935A1 (de) *	1984-05-28	1985-11-28	Merck Patent Gmbh, 6100 Darmstadt	Verwendung von hydroxyindolderivaten bei der senkung des blutdrucks
GB2162522B (en) *	1984-08-01	1988-02-24	Glaxo Group Ltd	An indole derivative
US4548939A (en) *	1984-10-01	1985-10-22	Janssen Pharmaceutica N. V.	1H-Indol-3-yl containing 1,3-dimethyl-1H-purine-2,6-diones
IT1181741B (it) *	1984-12-04	1987-09-30	Glaxo Group Ltd	Derivati di indolo,procedimento per prepararli e composizioni farmaceutiche che li contengono
IE58370B1 (en) *	1985-04-10	1993-09-08	Lundbeck & Co As H	Indole derivatives
GB8819024D0 (en) *	1988-08-10	1988-09-14	Glaxo Group Ltd	Chemical compounds
GB8903036D0 (en) *	1989-02-10	1989-03-30	Glaxo Group Ltd	Chemical compounds

1988
- 1988-08-12 AU AU20692/88A patent/AU611469B2/en not_active Expired
- 1988-08-12 KR KR88010367A patent/KR0131327B1/ko not_active Expired - Lifetime
- 1988-08-12 NZ NZ225820A patent/NZ225820A/xx unknown
- 1988-08-12 DE DE88307499T patent/DE3882614T2/de not_active Expired - Lifetime
- 1988-08-12 EP EP88307499A patent/EP0303507B1/fr not_active Expired - Lifetime
- 1988-08-12 IL IL87437A patent/IL87437A0/xx not_active IP Right Cessation
- 1988-08-12 JP JP63201839A patent/JPH0633252B2/ja not_active Expired - Lifetime
- 1988-08-12 NO NO883587A patent/NO174052C/no not_active IP Right Cessation
- 1988-08-12 PH PH37409A patent/PH24976A/en unknown
- 1988-08-12 IE IE247788A patent/IE61488B1/en not_active IP Right Cessation
- 1988-08-12 CA CA000574643A patent/CA1310968C/fr not_active Expired - Lifetime
- 1988-08-12 PT PT88255A patent/PT88255B/pt not_active IP Right Cessation
- 1988-08-12 AT AT88307499T patent/ATE92057T1/de active
- 1988-08-12 GB GB8819200A patent/GB2208646B/en not_active Expired - Lifetime
- 1988-08-12 ES ES88307499T patent/ES2058292T3/es not_active Expired - Lifetime
- 1988-08-12 US US07/231,274 patent/US4997841A/en not_active Expired - Lifetime
- 1988-08-12 FI FI883744A patent/FI92397C/fi not_active IP Right Cessation
- 1988-08-12 DK DK198804554A patent/DK172696B1/da not_active IP Right Cessation
- 1988-08-13 SK SK4042-91A patent/SK281495B6/sk unknown
1991
- 1991-12-23 CZ CS914042A patent/CZ404291A3/cs unknown
1993
- 1993-05-19 SG SG653/93A patent/SG65393G/en unknown
- 1993-08-19 HK HK867/93A patent/HK86793A/xx not_active IP Right Cessation
- 1993-09-23 UY UY23657A patent/UY23657A1/es not_active IP Right Cessation
1994
- 1994-05-06 CY CY172894A patent/CY1728A/en unknown
1995
- 1995-06-30 HU HU95P/P00631P patent/HU211576A9/hu unknown
- 1995-12-14 LV LV950371A patent/LV5736B4/xx unknown
1997
- 1997-09-10 NL NL970035C patent/NL970035I2/nl unknown
- 1997-10-31 LU LU90160C patent/LU90160I2/fr unknown
1998
- 1998-02-05 NO NO1998008C patent/NO1998008I1/no unknown
- 1998-08-12 DE DE19983883614 patent/DE19775082I2/de active Active

Also Published As

Publication number	Publication date
KR0131327B1 (en)	1998-04-17
CA1310968C (fr)	1992-12-01
DE3882614T2 (de)	1993-11-18
PT88255A (pt)	1989-06-30
FI92397C (fi)	1994-11-10
HU211576A9 (en)	1995-12-28
GB2208646A (en)	1989-04-12
DK455488D0 (da)	1988-08-12
SG65393G (en)	1993-08-06
EP0303507B1 (fr)	1993-07-28
NZ225820A (en)	1990-09-26
IE61488B1 (en)	1994-11-02
NL970035I1 (nl)	1997-11-03
ES2058292T3 (es)	1994-11-01
SK281495B6 (sk)	2001-04-09
NL970035I2 (nl)	1998-01-05
NO174052C (no)	1994-03-09
JPH0633252B2 (ja)	1994-05-02
PH24976A (en)	1990-12-26
PT88255B (pt)	1995-03-01
LV5736B4 (lv)	1997-06-20
NO883587D0 (no)	1988-08-12
AU2069288A (en)	1989-02-16
EP0303507A2 (fr)	1989-02-15
KR890003731A (ko)	1989-04-17
UY23657A1 (es)	1994-02-25
FI883744A0 (fi)	1988-08-12
NO883587L (no)	1989-02-14
ATE92057T1 (de)	1993-08-15
GB8819200D0 (en)	1988-09-14
DK455488A (da)	1989-02-14
CZ404291A3 (en)	1993-04-14
JPH01207288A (ja)	1989-08-21
IL87437A0 (en)	1989-01-31
DE3882614D1 (de)	1993-09-02
NO1998008I1 (no)	1998-02-05
FI92397B (fi)	1994-07-29
IE882477L (en)	1989-02-13
AU611469B2 (en)	1991-06-13
LV5736A4 (lv)	1996-06-20
NO174052B (no)	1993-11-29
HK86793A (en)	1993-08-27
CY1728A (en)	1994-05-06
DE19775082I2 (de)	2006-04-27
EP0303507A3 (en)	1990-09-19
FI883744L (fi)	1989-02-14
GB2208646B (en)	1991-06-26
US4997841A (en)	1991-03-05
SK404291A3 (en)	2000-09-12
DK172696B1 (da)	1999-05-31

Publication	Publication Date	Title
LU90160I2 (fr)	1998-01-14	Naratriptan facultativement sous la forme d'un sel pharmaceutiquement acceptable ou d'un solvate y compris le chlorhydrate de naratriptan
DK391289D0 (da)	1989-08-09	Indolderivater
ATE103812T1 (de)	1994-04-15	Zusammensetzung zur behandlung von ischaemischen stoerungen in organen.
CA2203274A1 (fr)	1996-05-09	Inhibiteurs de synthese d'apolipoproteines-b
DE69008142D1 (de)	1994-05-19	4-Substituierten Imidazolen zur Senkung des intraokularen Druckes.
MY132062A (en)	2007-09-28	Apolipoprotein-b synthesis inhibitors
IL106445A0 (en)	1993-11-15	4-substituted 1,2,4-triazole derivatives,their preparation and pharmaceutical compositions containing them
EP0555479A4 (fr)	1994-02-09
MY103509A (en)	1993-06-30	Indole derivatives.
TNSN93081A1 (fr)	1994-03-17	Procede de preparation de derives de la n-(phenylethyl-b-ol) amine